• Wed news: BioNTech buying Biotheus. FDA’s Califf lists hopes for his successor. Amgen loses $12B market cap from hidden spreadsheet tab. TRex Bio raises $84M. London is Europe’s life science capitol. See more on our front page

Gamida lays off 17%, ditches NK cell therapy work to keep blood cancer drug on track

Quote
cafead

cafead

Administrator
Staff member
  • cafead   Mar 27, 2023 at 10:02: AM
via More than a year after Gamida Cell slimmed down its workforce, the biotech has again resorted to laying off staff to keep the long-delayed plans for its blood cancer treatment omidubicel on the road.

article source
 




Top Bottom
Back
Quote